Retatrutide + GHK-Cu
No trial has tested these two together, and the skin problem people are trying to solve is mostly elastin.
The reason people pair these is specific and reasonable: retatrutide produces the largest weight loss any drug has published, and loose skin is the thing they are told to expect. GHK-Cu is the peptide most associated with collagen. The difficulty is that stretched skin is a collagen problem and an elastin problem, and adult skin barely makes new elastin.
Losing the weight, and dreading the skin.
The worry behind this pairing is a real one, and the people raising it are not being irrational. Someone watching 30 kilograms come off over eighteen months has a reasonable question about what the skin will do. The internet has told them the answer is loose folds that only surgery removes.
GHK-Cu is the obvious thing to reach for. It has four decades of research behind it, most of that research is about collagen and tissue repair, and collagen is what people understand firmness to be made of.
The combination comes up in weight loss communities rather than in bodybuilding ones. That fits the motivation. We found discussion of it across the retatrutide and biohacking subreddits, and the signal is real without being large.[1]
No trial has tested the two compounds together, in any population, for any outcome. Nothing published measures what injected GHK-Cu does to skin during or after rapid weight loss.
Four benefits, and how well each one holds up.
The second row is genuine and it describes a different problem from the third. Facial wrinkle depth over eight weeks and a hanging abdominal fold after 30 kilograms are not the same measurement.
Three questions, answered before anything else.
Collagen rebuilds. Elastin mostly does not.
Skin holds its shape through two different proteins in the dermis. Collagen supplies strength and structure. Elastin supplies the recoil, the property that lets skin return toward its previous shape after being stretched.
Those two proteins behave very differently over a lifetime. Fibroblasts keep producing collagen into adulthood, at a declining rate. Elastin is close to a fixed inheritance. Gene expression drops to negligible levels after puberty, and racemization studies show the elastin in adult skin was synthesised decades earlier with minimal turnover since.[2]
One review of the chemistry puts it flatly, saying that adult dermal fibroblasts cannot repair or replace damaged elastic fibres in skin.[3]
That matters for this stack because of what biopsy work has found in people after massive weight loss. Skin samples showed lower collagen density and thickness together with damaged elastic fibres, and a shift away from thick organised collagen bundles toward thin disorganised ones.[4]
GHK-Cu's documented action is weighted heavily toward the half of that problem the body can already address. Signalling for more collagen in skin whose elastic fibres are damaged is working on the component that was never the limiting one. Our guide on what happens to skin after significant weight loss covers what has and has not been shown to change it.
There is a reasonable objection to that argument and it deserves stating. GHK-Cu incubated with human adult dermal fibroblasts increased the production of elastin as well as collagen, at concentrations from 0.01 to 100 nanomolar.[13] The 2016 wrinkle trial was titled for collagen and elastin production, so the researchers were looking at both.[6]
Cells in a dish producing tropoelastin is a different claim from damaged elastic fibres in adult skin being rebuilt and cross-linked into a working network. No human study has measured elastin in skin after GHK-Cu by any route, and none has measured it after weight loss. The in vitro signal is real, and it is a reason to want the study rather than a substitute for it.
Real trials, and all of them topical.
GHK-Cu is not a weak compound, and dismissing it would be wrong. It has more than four decades of preclinical evidence for tissue regeneration and gene expression remodelling, and genuine controlled human studies.[5]
Those human studies share a shape. A 2016 randomised double-blind trial followed 40 women aged 40 to 65 using a topical formulation over eight weeks, measuring wrinkle depth and volume.[6] Others have measured facial laxity, firmness, density and thickness over periods counted in weeks.[6]
Every one of them applied the compound to skin. One evidence review comparing the two routes concludes that no published human clinical trial has evaluated injectable GHK-Cu for any indication, while listing multiple controlled human studies on the topical side.[7] A 2026 systematic review of microneedle delivery makes a similar point about that route, noting it has yet to be evaluated in a single registered, adequately powered human randomised trial.[5]
Our guide on the three different products sold as GHK-Cu goes through the route question properly. The short version for this page is that the evidence people cite when buying vials was generated by a cream.
Vendor pages routinely bridge that gap with confidence. One states that injectable GHK-Cu delivers significantly higher bioavailability and typically produces more pronounced results for established skin laxity. That is a claim about a route with no trials behind it.[8]
What retatrutide's trial produced.
The concern behind this stack is proportionate to the weight loss, so the trial numbers are worth having in front of you.
TRIUMPH-1 randomised adults with obesity or overweight plus a weight-related condition. At 80 weeks the 12 mg arm lost 28.3 percent of body weight on average, against roughly 2 percent on placebo, from a mean baseline around 112 kilograms.[9]
The distribution matters more than the mean for this question. In that arm, 62.5 percent lost at least a quarter of their body weight, 45.3 percent lost at least 30 percent, and 27.2 percent lost at least 35 percent.[9] A prespecified extension in participants with higher starting BMI reached 30.3 percent at 104 weeks.[9]
Losing a third of your body weight over eighteen months is the kind of change that historically followed bariatric surgery, and loose skin is a well-documented consequence of that. The worry is not manufactured by vendors.
One thing the trial did not measure is body composition. Our news piece on the published TRIUMPH-1 results covers that gap, and the guide to skin changes on retatrutide covers what people report during treatment.
What is documented, and what is convention.
People running GHK-Cu alongside anything else usually encounter advice about copper. Some of that advice rests on published chemistry and some on community practice, and the two are worth separating.
Documented. Copper in its reactive form can oxidise cysteine and methionine side chains. One clinical guide therefore advises against mixing GHK-Cu with other peptides in the same syringe without stability data, suggesting separate injections instead.[10] The same source describes copper accumulation at doses well above the physiological range as a real concern, noting that chronic copper loading stresses hepatic clearance and compounds with dietary intake.[10]
Also documented, and more recent. A September 2026 NPR report quoted a dermatologist describing patients who arrived with elevated liver enzymes and elevated copper after injecting large amounts without checking lab work. That same report notes it is unclear whether the copper peptide, other undisclosed substances, or impurities were responsible.[11] It also records that an FDA advisory panel was due to meet in February to review the evidence for GHK-Cu as an injectable.[11]
Convention. Specific stability claims about particular peptide pairings, timing rules about which compound goes first, and advice about balancing copper against zinc intake circulate widely without published data attached. The underlying chemistry is real. The specific protocols are not measured.
Neither we nor the sources we found have stability data for GHK-Cu alongside retatrutide specifically. Anyone taking both has a straightforward reason to ask a doctor about copper and liver markers rather than to work it out from forum threads.
Two vials, and no premixed version.
Nobody sells these two together, so this is two separate purchases at whatever the market is charging today. Both compounds have wide spreads, and that matters more than the floor price.
GHK-Cu also appears in several premixed blends aimed at skin and repair. The GHK-Cu and BPC-157 pairing is the cheapest route into that category, and GLOW adds TB-500 on top.
The comparison that matters is not between these two vials. Topical GHK-Cu is the form with the human trials, costs less than injectable vials in most cases, and is sold through ordinary cosmetic channels.
One drug awaiting approval, one compound under review.
Retatrutide is approved nowhere. Its Phase 3 programme is complete and a US filing is planned, so everything sold online remains research chemical material.
GHK-Cu has no approval as an injectable anywhere. Topical formulations are sold as cosmetics under ordinary cosmetic rules, a different regulatory position from the vials.
An FDA advisory panel recommended reclassifying several peptides during 2026 and was scheduled to review GHK-Cu as an injectable in February.[11] That review may change what compounding pharmacies can do with it, so the position described here has a date attached to it.
For anyone losing weight at the rate TRIUMPH-1 describes, the useful conversation with a doctor is about protein intake, resistance training and the realistic timeline for skin remodelling. All three have evidence behind them. Skin that has stretched over many years generally takes one to two years to retract as far as it is going to.[4]
What people ask about this stack
Does GHK-Cu prevent loose skin on retatrutide?
Nothing published has measured that. No trial has tested retatrutide and GHK-Cu together, and no study has measured GHK-Cu of any form against loose skin after major weight loss. The human evidence for GHK-Cu comes from topical trials measuring facial wrinkles, firmness and density over weeks. That is a different outcome in a different place on the body.
Why is elastin the problem rather than collagen?
Skin retracts because of elastin, and elastin is close to a fixed inheritance. Gene expression drops to negligible levels after puberty, and racemization studies show the elastin in adult skin was made decades earlier with minimal turnover. Collagen keeps being produced into adulthood. Biopsy work after massive weight loss finds both lower collagen density and damaged elastic fibres. A compound that signals for collagen therefore addresses the half of the problem the body was already addressing. GHK-Cu has increased elastin production in human fibroblasts in a dish. That is worth knowing, and it is not the same as rebuilding damaged fibres in skin.
Does injectable GHK-Cu have human trials?
No. One evidence review comparing the routes states that no published human clinical trial has evaluated injectable GHK-Cu for any indication, while listing multiple controlled human studies for the topical form. A 2026 systematic review of microneedle delivery reports the same gap for that route. Vendor pages that describe injection as more effective are making a claim about a route with no trials behind it.
How much weight do people lose on retatrutide?
In TRIUMPH-1 the 12 mg arm lost 28.3 percent of body weight on average at 80 weeks, against roughly 2 percent on placebo, from a mean baseline around 112 kilograms. Within that arm, 45.3 percent lost at least 30 percent of their body weight and 27.2 percent lost at least 35 percent. Participants with higher starting BMI who continued to 104 weeks averaged 30.3 percent in a prespecified extension.
Should GHK-Cu be mixed with other peptides?
One clinical guide advises against mixing it in the same syringe without stability data, on the grounds that copper in its reactive form can oxidise cysteine and methionine side chains. It suggests separate injections instead. That chemistry is documented. The specific protocols circulating about which compound goes first, or how to balance copper against zinc, are community convention without published data behind them. No stability data exists for GHK-Cu alongside retatrutide specifically.
What helps with loose skin after major weight loss?
Mild laxity often improves over one to two years as collagen remodels, particularly in younger people who lost weight steadily. For a substantial skin excess the evidence points to surgical removal as the only reliable option, and no supplement or peptide has been shown to shrink hanging folds. Protein intake and resistance training support the parts that are modifiable. Compare against the other stacks.
What this page is built on
- 01Community discussion of retatrutide with GHK-Cu, including r/Retatrutide, 27 September 2026 and r/Biohacking, the latter covering retatrutide with tesamorelin and GHK-Cu.
- 02Elastin in adult skin. Source for ELN gene expression dropping to negligible levels after puberty, for adult fibroblasts producing very little new tropoelastin, and for amino acid racemization studies confirming that the elastin present in adult skin was synthesised decades earlier with minimal turnover. Also the source for the contrast with collagen, meaningfully regenerated through fibroblast stimulation.
- 03Elastic fibre biology, from the background sections of several granted US patents on elastin production. Source for tropoelastin synthesis and cross-linking, for the statement that dermal fibroblasts lose their ability to make elastin by the end of puberty and that adult dermal fibroblasts cannot repair or replace damaged elastic fibres in skin, and for elastic fibres not undergoing extensive turnover.
- 04Loose skin after weight loss. Source for skin samples in patients with massive weight loss showing lower collagen density and thickness together with damaged elastic fibres, for a 2021 Obesity Surgery biopsy study finding a shift from thick organised collagen bundles toward thin disorganised fibres, for mild laxity often improving over 12 to 24 months as collagen remodels, for surgical removal being the only reliable option for significant excess skin, and for no study having shown supplements meaningfully tightening loose skin after major weight loss.
- 05A systematic review of the mechanisms and therapeutic applications of GHK-Cu in topical microneedle delivery. PMC13604022. Source for more than four decades of preclinical evidence on tissue regeneration and gene-expression remodelling, and for microneedle-mediated delivery not yet having been evaluated in a single registered, adequately powered human randomised controlled trial published in the peer-reviewed literature.
- 06Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z. Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production, and facial wrinkle parameters. Journal of Aging Science, 2016. Record. Randomised double-blind trial, 40 female volunteers aged 40 to 65, twice-daily topical GHK-Cu in a lipid-based nano-carrier over 8 weeks, analysed on 39. Wrinkle volume fell 55.8 percent and depth 32.8 percent against control serum, and volume fell 31.6 percent against a Matrixyl 3000 comparator. Separately, the source for human topical research having measured wrinkle appearance, laxity, firmness, density and thickness over periods counted in weeks, and for that evidence not establishing that a topical peptide removes excess tissue after major weight loss.
- 07GHK-Cu topical versus injectable evidence comparison. Source for the statement that no published human clinical trial has evaluated injectable GHK-Cu for any indication, against multiple controlled human studies for the topical route covering wrinkle reduction, collagen stimulation and post-procedure healing.
- 08A vendor page stating that injectable GHK-Cu delivers significantly higher bioavailability than topical formulations and typically produces more pronounced results for established skin laxity. Recorded here because no human trial of injectable GHK-Cu has been published.
- 09TRIUMPH-1, Phase 3 obesity trial of retatrutide, topline results announced 21 May 2026 and subsequently published. At 80 weeks mean body weight reduction was 19.0 percent at 4 mg, 25.9 percent at 9 mg and 28.3 percent at 12 mg, against 2.2 percent with placebo, from a mean baseline body weight of 112.7 kg. In the 12 mg arm 62.5 percent reached at least 25 percent weight loss, 45.3 percent at least 30 percent and 27.2 percent at least 35 percent. A prespecified extension in participants with higher starting BMI reached 30.3 percent at 104 weeks.
- 10Clinical guide to GHK-Cu injections. Source for copper in its reactive form oxidising cysteine and methionine side chains in co-administered peptides, for mixing in the same syringe not being recommended without stability data with sequential separate injections reducing that risk, and for copper accumulation at doses substantially above the physiological range stressing hepatic copper clearance and compounding with dietary intake.
- 11The copper peptide trend has gone from creams to injections, ahead of the science. NPR, 7 September 2026. Article. Source for a dermatologist describing patients presenting with elevated liver enzymes and elevated copper after injecting large amounts without lab monitoring, for the accompanying caveat that attribution to the copper peptide rather than impurities or undisclosed substances is unclear, and for an FDA advisory panel having recommended reclassifying several peptides with a February meeting scheduled to review GHK-Cu as an injectable.
- 12Peptide Decoding vendor pricing data. Lowest in-stock single-compound listings for retatrutide and GHK-Cu, with listing counts, computed at page load. No premixed listing combines the two compounds.
- 13Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 2018. PMC6073405, PMID 29986520. Source for GHK-Cu at 0.01, 1 and 100 nanomolar incubated with human adult dermal fibroblasts increasing production of both elastin and collagen, for a facial cream applied for 12 weeks to 71 women increasing skin density and thickness and reducing laxity, for an eye cream over 12 weeks in 41 women outperforming placebo and vitamin K cream, and for GHK-Cu applied to thigh skin improving collagen production in 70 percent of women against 50 percent for vitamin C and 40 percent for retinoic acid.